A study assessing OKYO-0201 for ocular pain
Latest Information Update: 22 Aug 2019
Price :
$35 *
At a glance
- Drugs OK 201 (Primary)
- Indications Ocular pain
- Focus Adverse reactions
- 22 Aug 2019 New trial record
- 19 Aug 2019 According to a OKYO Pharma media release, the company is planning to file an IND by the second quarter in 2021.